Concepts (195)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Facial Dermatoses | 3 | 2018 | 87 | 0.820 |
Why?
|
| Carcinoma, Basal Cell | 6 | 2018 | 545 | 0.700 |
Why?
|
| Dermatitis Herpetiformis | 1 | 2019 | 26 | 0.700 |
Why?
|
| Sulfasalazine | 1 | 2019 | 79 | 0.680 |
Why?
|
| Vitiligo | 1 | 2019 | 89 | 0.650 |
Why?
|
| Mohs Surgery | 3 | 2019 | 197 | 0.640 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 2018 | 85 | 0.620 |
Why?
|
| Bandages | 1 | 2019 | 266 | 0.600 |
Why?
|
| Radio Waves | 1 | 2018 | 251 | 0.590 |
Why?
|
| Onychomycosis | 9 | 2001 | 47 | 0.540 |
Why?
|
| Porokeratosis | 1 | 2014 | 4 | 0.510 |
Why?
|
| Skin | 8 | 2019 | 4364 | 0.490 |
Why?
|
| Lasers, Dye | 2 | 2011 | 29 | 0.480 |
Why?
|
| Sunbathing | 1 | 2014 | 60 | 0.470 |
Why?
|
| Keratosis, Actinic | 3 | 2022 | 74 | 0.450 |
Why?
|
| Skin Neoplasms | 10 | 2021 | 5686 | 0.400 |
Why?
|
| Celiac Disease | 1 | 2019 | 785 | 0.400 |
Why?
|
| Fluorouracil | 4 | 2018 | 1619 | 0.390 |
Why?
|
| Wound Healing | 2 | 2019 | 2785 | 0.390 |
Why?
|
| Pruritus | 1 | 2014 | 361 | 0.390 |
Why?
|
| Antifungal Agents | 9 | 2001 | 730 | 0.370 |
Why?
|
| Leg Dermatoses | 1 | 2008 | 20 | 0.330 |
Why?
|
| Itraconazole | 3 | 2001 | 43 | 0.290 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2008 | 151 | 0.290 |
Why?
|
| Naphthalenes | 3 | 2001 | 194 | 0.270 |
Why?
|
| Dermatomyositis | 1 | 2008 | 224 | 0.270 |
Why?
|
| Drug Eruptions | 1 | 2008 | 297 | 0.260 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2016 | 640 | 0.230 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2018 | 4034 | 0.220 |
Why?
|
| Zinc Oxide | 1 | 2022 | 21 | 0.220 |
Why?
|
| Ultraviolet Therapy | 2 | 2014 | 81 | 0.200 |
Why?
|
| Melanosis | 1 | 2022 | 78 | 0.200 |
Why?
|
| Tranexamic Acid | 1 | 2022 | 146 | 0.190 |
Why?
|
| Powders | 1 | 2019 | 80 | 0.170 |
Why?
|
| Fluconazole | 4 | 2000 | 146 | 0.160 |
Why?
|
| Laser Therapy | 2 | 2016 | 1072 | 0.160 |
Why?
|
| Biopsy | 4 | 2019 | 6756 | 0.150 |
Why?
|
| Granuloma | 1 | 2019 | 319 | 0.150 |
Why?
|
| Psoriasis | 2 | 2019 | 898 | 0.150 |
Why?
|
| Chemoprevention | 1 | 2018 | 319 | 0.130 |
Why?
|
| Lasers, Gas | 1 | 2016 | 93 | 0.130 |
Why?
|
| Sarcoidosis | 1 | 2019 | 506 | 0.120 |
Why?
|
| Foot Dermatoses | 6 | 2001 | 44 | 0.100 |
Why?
|
| Mechlorethamine | 1 | 1991 | 136 | 0.100 |
Why?
|
| Dermatology | 1 | 2022 | 872 | 0.100 |
Why?
|
| Ultraviolet Rays | 2 | 2007 | 1060 | 0.100 |
Why?
|
| Epidermal Cyst | 1 | 1991 | 62 | 0.100 |
Why?
|
| Aged, 80 and over | 10 | 2019 | 57776 | 0.090 |
Why?
|
| Carcinoma in Situ | 1 | 2016 | 806 | 0.090 |
Why?
|
| Drug Administration Schedule | 7 | 2018 | 4933 | 0.090 |
Why?
|
| Veterans | 2 | 2021 | 2519 | 0.090 |
Why?
|
| Tinea Capitis | 2 | 2000 | 12 | 0.090 |
Why?
|
| Melanoma | 2 | 2019 | 5510 | 0.090 |
Why?
|
| Male | 31 | 2022 | 350118 | 0.090 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 1991 | 207 | 0.090 |
Why?
|
| Administration, Cutaneous | 3 | 2018 | 711 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 2282 | 0.080 |
Why?
|
| Administration, Topical | 4 | 2015 | 690 | 0.080 |
Why?
|
| Humans | 39 | 2022 | 744343 | 0.080 |
Why?
|
| Middle Aged | 20 | 2019 | 213383 | 0.080 |
Why?
|
| Venous Insufficiency | 1 | 2008 | 103 | 0.070 |
Why?
|
| Single-Blind Method | 3 | 2016 | 1590 | 0.070 |
Why?
|
| Aged | 20 | 2021 | 163280 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 5391 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 12959 | 0.070 |
Why?
|
| Radiation-Protective Agents | 1 | 2006 | 90 | 0.070 |
Why?
|
| Ambulatory Care | 1 | 2017 | 2708 | 0.070 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2007 | 108 | 0.070 |
Why?
|
| Carcinoma | 1 | 2017 | 2375 | 0.070 |
Why?
|
| Treatment Outcome | 13 | 2022 | 63114 | 0.060 |
Why?
|
| Carboplatin | 1 | 2008 | 801 | 0.060 |
Why?
|
| Interleukin-1 | 1 | 1989 | 1263 | 0.060 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2006 | 708 | 0.060 |
Why?
|
| Keratosis | 1 | 2004 | 81 | 0.060 |
Why?
|
| Aminolevulinic Acid | 1 | 2004 | 142 | 0.060 |
Why?
|
| Skin Diseases | 1 | 1991 | 1065 | 0.050 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2007 | 709 | 0.050 |
Why?
|
| Hydroquinones | 1 | 2022 | 36 | 0.050 |
Why?
|
| Fluocinolone Acetonide | 1 | 2022 | 36 | 0.050 |
Why?
|
| Skin Aging | 1 | 2004 | 127 | 0.050 |
Why?
|
| Leg | 2 | 2019 | 1116 | 0.050 |
Why?
|
| Sunlight | 1 | 2004 | 325 | 0.050 |
Why?
|
| Incidence | 2 | 2019 | 20947 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2022 | 5788 | 0.050 |
Why?
|
| Sunscreening Agents | 1 | 2022 | 132 | 0.050 |
Why?
|
| Mitosporic Fungi | 1 | 2001 | 20 | 0.050 |
Why?
|
| Silicones | 1 | 2022 | 250 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2008 | 1708 | 0.050 |
Why?
|
| Female | 22 | 2022 | 380194 | 0.050 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 39050 | 0.050 |
Why?
|
| Telemedicine | 1 | 2017 | 2872 | 0.040 |
Why?
|
| Photosensitizing Agents | 1 | 2004 | 602 | 0.040 |
Why?
|
| Tretinoin | 1 | 2022 | 517 | 0.040 |
Why?
|
| Skin Ulcer | 1 | 2019 | 120 | 0.040 |
Why?
|
| Nail Diseases | 1 | 1998 | 51 | 0.040 |
Why?
|
| Double-Blind Method | 5 | 2018 | 12026 | 0.040 |
Why?
|
| Photochemotherapy | 1 | 2004 | 807 | 0.040 |
Why?
|
| Tumor Burden | 2 | 2016 | 1915 | 0.040 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2000 | 550 | 0.040 |
Why?
|
| Mentors | 1 | 2022 | 631 | 0.040 |
Why?
|
| Keratinocytes | 1 | 2021 | 798 | 0.040 |
Why?
|
| Erythromycin | 1 | 1996 | 120 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2018 | 10943 | 0.030 |
Why?
|
| New England | 1 | 2019 | 1022 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 8642 | 0.030 |
Why?
|
| Necrosis | 1 | 2019 | 1643 | 0.030 |
Why?
|
| Melanins | 2 | 2007 | 289 | 0.030 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2019 | 875 | 0.030 |
Why?
|
| Prednisone | 1 | 2019 | 1574 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 1641 | 0.030 |
Why?
|
| Skin Transplantation | 1 | 2019 | 1074 | 0.030 |
Why?
|
| Adult | 13 | 2019 | 214055 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2001 | 6489 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2022 | 1855 | 0.030 |
Why?
|
| Time Factors | 4 | 2019 | 40075 | 0.030 |
Why?
|
| PUVA Therapy | 1 | 1991 | 98 | 0.020 |
Why?
|
| Ovarian Neoplasms | 1 | 2008 | 4838 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 1998 | 1359 | 0.020 |
Why?
|
| Extremities | 1 | 2016 | 865 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 7181 | 0.020 |
Why?
|
| Retrospective Studies | 4 | 2021 | 77449 | 0.020 |
Why?
|
| Ontario | 2 | 2000 | 383 | 0.020 |
Why?
|
| Recurrence | 1 | 2019 | 8340 | 0.020 |
Why?
|
| Eccrine Glands | 1 | 2007 | 45 | 0.020 |
Why?
|
| Thymidine | 1 | 2007 | 310 | 0.020 |
Why?
|
| Child | 6 | 2017 | 77709 | 0.020 |
Why?
|
| Risk Factors | 5 | 2019 | 72290 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2007 | 290 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 11366 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 13695 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2016 | 2219 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2018 | 10252 | 0.020 |
Why?
|
| Infant | 4 | 2017 | 35136 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2009 | 973 | 0.020 |
Why?
|
| Prospective Studies | 4 | 2001 | 53288 | 0.020 |
Why?
|
| Thorax | 1 | 2007 | 547 | 0.020 |
Why?
|
| Ointments | 1 | 2004 | 59 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2006 | 813 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 3396 | 0.010 |
Why?
|
| Child, Preschool | 4 | 2017 | 41006 | 0.010 |
Why?
|
| United States | 3 | 2021 | 69872 | 0.010 |
Why?
|
| Melanocytes | 1 | 2007 | 515 | 0.010 |
Why?
|
| Smoking | 1 | 2000 | 8987 | 0.010 |
Why?
|
| Age Distribution | 2 | 2000 | 2902 | 0.010 |
Why?
|
| Cohort Studies | 2 | 2021 | 40561 | 0.010 |
Why?
|
| Registries | 1 | 2019 | 8089 | 0.010 |
Why?
|
| Epidermis | 1 | 2006 | 528 | 0.010 |
Why?
|
| Medicare | 1 | 2021 | 6566 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 11031 | 0.010 |
Why?
|
| Pulse Therapy, Drug | 1 | 2001 | 35 | 0.010 |
Why?
|
| Adolescent | 6 | 2017 | 85781 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 15540 | 0.010 |
Why?
|
| Urea | 1 | 2004 | 450 | 0.010 |
Why?
|
| Kinetics | 1 | 1989 | 6473 | 0.010 |
Why?
|
| Quality of Life | 1 | 2022 | 12804 | 0.010 |
Why?
|
| Microsporum | 1 | 2000 | 5 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 2017 | 25625 | 0.010 |
Why?
|
| Lidocaine | 1 | 2004 | 544 | 0.010 |
Why?
|
| Trichophyton | 1 | 2000 | 17 | 0.010 |
Why?
|
| Hand Dermatoses | 1 | 2000 | 61 | 0.010 |
Why?
|
| Antibodies | 1 | 1989 | 2460 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2007 | 2924 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2007 | 3616 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1989 | 6622 | 0.010 |
Why?
|
| Arthrodermataceae | 1 | 1998 | 7 | 0.010 |
Why?
|
| Cell Division | 1 | 2006 | 4568 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2009 | 2728 | 0.010 |
Why?
|
| Bacteria, Aerobic | 1 | 1996 | 25 | 0.010 |
Why?
|
| DNA Damage | 1 | 2007 | 2432 | 0.010 |
Why?
|
| Prognosis | 1 | 2018 | 29063 | 0.010 |
Why?
|
| Coagulase | 1 | 1996 | 54 | 0.010 |
Why?
|
| Anesthetics, Local | 1 | 2004 | 985 | 0.010 |
Why?
|
| Staphylococcus | 1 | 1996 | 155 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2018 | 23338 | 0.010 |
Why?
|
| Nails | 1 | 1998 | 292 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2007 | 3474 | 0.010 |
Why?
|
| Drug Resistance, Multiple | 1 | 1996 | 252 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2000 | 2297 | 0.010 |
Why?
|
| Canada | 1 | 2000 | 2065 | 0.010 |
Why?
|
| Probability | 1 | 2000 | 2505 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2000 | 2971 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2000 | 1877 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1996 | 862 | 0.010 |
Why?
|
| Genes, Bacterial | 1 | 1996 | 1079 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 1999 | 1782 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2007 | 10481 | 0.010 |
Why?
|
| Young Adult | 1 | 2017 | 56430 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2006 | 19229 | 0.010 |
Why?
|
| Health Surveys | 1 | 2000 | 4037 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2001 | 2684 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2000 | 9849 | 0.000 |
Why?
|
| Comorbidity | 1 | 2000 | 10388 | 0.000 |
Why?
|
| Boston | 1 | 1998 | 9313 | 0.000 |
Why?
|
| Age Factors | 1 | 2001 | 18370 | 0.000 |
Why?
|
| Prevalence | 1 | 1998 | 15226 | 0.000 |
Why?
|
Concepts
(195)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(4)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_